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Abstract 
Aim: To assess functional beta cell capacity in type 2 diabetes during 2 years of remission 
induced by dietary weight loss.  
Methods: A Stepped Insulin Secretion Test with Arginine (SISTA) was used to quantify 
functional beta cell capacity by hyperglycemia and arginine stimulation. 39/57 subjects 
initially achieved remission (HbA1c<6.5% (<48mmol/mol) and FPG <7 mmol/l on no anti-
diabetic drug therapy) with 16.4±7.7 kg weight loss, and were followed up with supportive 
advice on avoidance of weight regain. At 2 years, 20 subjects remained in remission in the 
study. A Non-Diabetic Control (NDC) group, matched for age/sex/weight after weight loss 
with the intervention group, was studied once.  
Results: During remission, median [IQ range] maximal rate of insulin secretion increased 
from  581 [480-811] at baseline to  736 [542-998] at 5 months, 942 [565-1240] at 12 months 
(p=0.028 from baseline), and 936 [635-1435] pmol/min/m2 at 24 months (p=0.023 from 
baseline; n=20/39 of those initially in remission). This was comparable to NDC (1016 [857-
1507] pmol/min/m2) by 12 (p=0.064) and 24 months (p=0.244).  
Median first phase insulin response increased from baseline to 5 months (42 [4-67] to 107 
[59-163] pmol/min/m2; p<0.0001), then remained stable at 12 and 24 months (110 [59-201] 
and 125 [65-166] pmol/min/m2 respectively; p<0.0001 vs. baseline) but lower than that of 
the NDC group (250 [226-429] pmol/min/m2; p<0.0001). 
Conclusion: A gradual increase in assessed functional beta cell capacity occurred after 
weight loss, becoming similar to Non-Diabetic Controls by 12 months. This was unchanged 
at 2 years with continuing remission of type 2 diabetes. 
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Introduction 
Type 2 diabetes has long been known to be associated with decreased functional beta cell 
capacity. This has appeared to be progressive, resulting in requirement for insulin therapy in 
50% of people within 10 years of diagnosis (1). The early observation of decreased number 
of islets able to be isolated from the pancreas of people with type 2 diabetes (2) was 
followed by histological studies which reported 24-65% decrease in beta cell number 
compared with weight matched non-diabetic subjects (3, 4). However, the functional deficit 
has been reported to be greater than expected, with 50-97% decrease (5-7). Consistent with 
this, a 50% hemipancreatectomy does not bring about type 2 diabetes in most people (8).  
The decrease in overall beta cell function has been conventionally ascribed to beta cell 
death or apoptosis (3, 9, 10). This has been challenged by recent studies which have 
identified loss of beta cell insulin secretory function due to suppression of relevant genes 
(11-14). This dedifferentiation is potentially reversible. Our previous shorter term studies 
have shown that type 2 diabetes can be returned to non-diabetic glucose control following 
dietary weight loss (15-18). The seminal question is now how closely back to normal the 
functional beta cell capacity returns during two years remission of type 2 diabetes. 
DiRECT (the Diabetes Remission Clinical Trial) reported return to non-diabetic glucose 
control in over one third of a large Primary Care population of people with type 2 diabetes 
at two years using a simple, effective dietary method (17, 19, 20). There are few in vivo 
studies assessing functional beta cell capacity in type 2 diabetes, and none after reversal of 
type 2 diabetes (14, 21). We now report upon functional beta cell capacity as assessed by 
stepped hyperglycemic clamps plus arginine bolus in a geographically defined cohort of 
DiRECT participants. This was quantified together with first phase insulin secretion before 
and up to 24 months after substantial weight loss in type 2 diabetes, comparing those who 
achieved HbA1c < 6.5% (< 48 mmol/mol) and fasting plasma glucose < 7.0 mmol/l) with 
those who remained in the diabetic range. For comparison, an additional group of Non-
Diabetic Controls were studied.  
 
Methods 
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Participants 
Participants in DiRECT had diabetes duration of less than 6 years, 20-65 years of age, BMI 
between 27 and 45 kg/m2, HbA1c ≥ 6.5% (≥ 48 mmol/mol) if on diet alone or HbA1c ≥ 6.1% 
(≥ 43 mmol/mol) if on treatment with oral hypoglycaemic agents.  Tyneside participants 
were randomised to Intervention (n=64) and Control (n=26) as previously reported (17, 19, 
20). Main exclusion criteria were: current insulin use, recent routine HbA1c ≥ 12% (≥ 108 
mmol/mol) and weight loss of >5 kg within the last 6 months. The Tyneside subgroup of 
DiRECT underwent insulin secretion studies.   A Non-Diabetic Control group (n=25) with no 
known first-degree history of type 2 diabetes was recruited to match the Intervention group 
at the post-weight loss time point for BMI, age, and gender, and an oral glucose tolerance 
test was performed to exclude any degree of glucose intolerance. Data on the DiRECT 
Control group of participants randomised to conventional therapy for type 2 diabetes are 
presented for completeness although the main comparison is between Responders and 
Non-Responders with the Non-Diabetic Control group as reference. 
Study protocol 
Weight loss and supportive weight maintenance was managed by Primary Care nurses with 
specific training on an integrated, structured, weight management programme 
(Counterweight-Plus)(19). All metabolic tests were performed at the Newcastle Magnetic 
Resonance Centre. After baseline tests, the Intervention group commenced a liquid formula 
diet (825–853 kcal/day) for an average of 16 weeks with continuation of all everyday 
activities. This was followed by a stepped food re-introduction phase. Thereafter, all 
participants were advised to follow a diet of normal foodstuffs to taste, but with individual 
advice and support to prevent weight regain. All oral hypoglycemic agents were withdrawn 
on Day 1 of the liquid formula diet. The Control group were continued on their usual 
diabetes management as per National Institute for Clinical Excellence guidelines. Beta cell 
function was assessed at baseline, after weight loss and return to normal eating at 5 
months, at 12 months and at 24 months for both Intervention and Control groups. Tests 
were carried out on the NDC group (n=25) on one occasion only. Height was measured using 
a portable stadiometer (Chasmors Ltd, London) and body weight was measured in the 
fasting state using calibrated digital scales (Seca Ltd., Birmingham, UK) immediately prior to 
studies at each time point. 
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In order to interpret the beta cell function data, the Intervention group was divided into 
Responders who achieved non-diabetic glucose control (HbA1c < 6.5% (< 48 mmol/mol) and 
fasting plasma glucose < 7.0 mmol/l) off all anti-diabetic agents and Non-Responders who 
did not fit these current criteria (19, 20, 22, 23). The Consort diagram (Figure S1) shows that 
the criteria were applied at the post-weight loss visit with Responders and Non-Responders 
being analysed separately. At 5 months, 40 of the 64 Intervention subjects achieved non-
diabetic plasma glucose control after the weight loss intervention and 39 Responders 
underwent the SISTA (Figure S1). One subject declined all the SISTA tests after baseline and 
counted as withdrawn. At 12 and 24 months, insulin secretion data were available on 28 and 
20 Responders and 16 and 12 Non-Responders respectively. To allow clear description of 
time course, those who achieved non-diabetic levels of HbA1c and fasting plasma glucose 
but subsequently relapsed were not added to the defined Non-Responder group. In the 
diabetic Control group data were available on 23 participants at baseline and 5 months, 20 
at 12 months, and 19 at 24 months. The Non-Diabetic Control group (n=25) was studied on 
one occasion.  
Ethical approval was obtained from the West of Scotland Research Ethics Committee 
(reference number: 13/WS/0314). 
 
Stepped Insulin Secretion Test with Arginine (SISTA) 
After an overnight fast of at least 10 hours, participants were transported to the Magnetic 
Resonance Centre. Only water was allowed to maintain hydration. Any diabetes medications 
were withdrawn on the evening prior to the test. The functional capacity of the beta cells 
was assessed using the Stepped Insulin Secretion Test with Arginine (SISTA) (24), as 
modified by Lim and colleagues (15). The schematic and details of performing the SISTA are 
shown in Figure S2. First phase insulin response is assessed as usual and the maximal 
capacity for insulin response under the conditions of the test is assessed following 
hyperglycemic clamping plus a bolus of arginine. 
Two large bore (18G) cannulae were inserted into forearm veins. Heat packs were used to 
allow sampling of arterialised blood.  After basal samples had been taken, a glucose bolus 
followed by 20% Glucose infusion (Appendix) achieved a square wave step increase in 
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plasma glucose level 2.8 mmol/l above basal during the first 30 minutes. A repeat bolus at 
30 minutes and increased infusion rate achieved steady state plasma glucose 5.6 mmol/l 
above fasting blood glucose for the rest of the test. A bolus of arginine (5 g) was 
administered over 30 seconds at 60 minutes. 
Insulin secretion rates were estimated by deconvolution from C-peptide concentrations. The 
ISEC computer program was used which applies a regularisation method of deconvolution 
giving an output of insulin secretion rate in pmol/min/m2 of body surface area (15, 25). This 
took account of gender, age, diabetes status, height, weight, body surface area and BMI. 
Data are reported on the assessed functional beta cell capacity (maximal rates of insulin 
secretion under the test conditions) and first phase response. Data are also reported for the 
insulin response to the second rapid increment in plasma glucose (‘second step response’) 
although the in vivo relevance of this is not yet established.  
Analytical Procedures 
Plasma glucose was measured by the glucose oxidase method (YSI glucose analyser, Yellow 
Springs Instrument Company, Yellow Springs, OH) and serum insulin and C-peptide by ELISA 
(Mercodia, Uppsala, Sweden). HbA1c was measured centrally at the Institute of 
Cardiovascular and Medical Sciences at Clinical Pathology Laboratory in Glasgow. Total 
fasting plasma triglyceride (TG) was quantified (Roche Diagnostics, West Sussex, U.K.) at the 
Department of Clinical Biochemistry, Newcastle upon Tyne Hospital National Health Service 
Foundation Trust. 
Statistical analysis 
Data were analysed by using IBM SPSS statistical software (www.ibm.com) using 
Independent Samples T test, Mann Whitney U test, and Spearman Rank correlation test as 
appropriate. The primary comparison between Responder and Non-Responder groups was 
the insulin secretion data. These were skewed in both groups and analysed non-
parametrically. Data are presented as median and interquartile range (25th and 75th 
centiles) or mean ± SD as appropriate. 
 
Results 
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Baseline comparison of Responders and Non-Responders  
At baseline, both Responders and Non-Responders had similar weight (100.4±16.6 vs 
102.1±18.8 kg). Fasting plasma insulin (FPI) in Responders was 86.4 [55.5-145.5] pmol/l and 
71.4 [51.5-100.6] pmol/l in Non-Responders (p=0.094). There were no significant differences 
between insulin secretion rates in Responders and Non-Responders at baseline although 
median rates of both maximal insulin secretion (581 [480-811] vs. 451 [296-691] 
pmol/min/m2; p=0.081) and first phase (42 [4-67] vs. 23 [10-36] pmol/min/m2; p=0.299) 
were higher in Responders. Responders and Non-Responders differed significantly in HbA1c 
(7.4±1.0% (57.5±10.6 mmol/mol) vs. 7.9±0.8% (62.5±8.8 mmol/mol); p=0.041) and duration 
of diabetes (2.7±1.6  vs. 3.8±1.6 years; p=0.026) respectively.  
 
Changes in weight and glucose control  
Responders and Non-Responders lost weight similarly at 5 months (Table 1). Weight 
increased in Responders by 3.2±4.2 kg between 5 and 12 months and by 6.6±4.3 kg between 
5 and 24 months. By design, weight of the Non-Diabetic Controls was similar to that of both 
study groups at 5 months (86.6±14.9 vs. 84.0±13.4 kg and 88.7±18.8 kg respectively) and 
remained similar at both 12 months (86.6±14.9 vs. 85.5±16.2 kg; p=0.845 and 92.5±18.3 kg; 
p=0.552 respectively) and 24 months (88.8±17.7 kg; p=0.648 and 90.3±14.6 kg; p=0.649 
respectively). Those who failed to maintain remission between 5 and 24 months were 
characterized by more weight regain (11.3±6.7 kg vs. 6.6±4.3 kg; p=0.036). There was no 
change  in weight in the Control group from baseline.    
HbA1c remained in the non-diabetic range in Responders (n=20) at 24 months having 
remained steady although significantly higher than in NDC (6.0±0.3% (41.7±3.5 mmol/mol) 
vs. 5.4±0.3% (35.2±3.4 mmol/mol); p<0.0001, Table 1). At 24 months mean HbA1c in 
Responders remained 6.0±0.3% (41.7±3.5 mmol/mol; p<0.0001 vs. NDC) and higher in Non-
Responders 8.1± 1.3% (65.3±14.4 mmol/mol; p<0.0001) despite their use of anti-diabetes 
medications. Controls and Non-Responders showed no change in HbA1c from baseline to 24 
months. Fasting plasma glucose level exhibited comparable changes to HbA1c in all groups 
(Table 1).  
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Fasting plasma insulin and C-peptide 
Fasting plasma insulin (FPI) decreased to similar levels in Responders and Non-Responders 
at 5 months (32.6 [19.6-53.3] vs. 33.8 [20.7-43.3] pmol/l respectively) and stayed similar at 
12 months (Table 1). The newly achieved level in both groups was similar to that of NDC 
(16.4 [10.0-37.2] pmol/l). At 24 months FPI stayed significantly lower than baseline in 
Responders (43.5 [18.4-61.6] pmol/l; p<0.0001) as well as in Non-Responders (34.4 [16.5-
49.5] pmol/l; p=0.001). FPI in Controls did not change significantly from baseline to 24 
months (70.1 [44.7-122.5] to 44.7 [31.3-64.5] pmol/l; p=0.050). In all groups, fasting C-
peptide exhibited a similar pattern of change to FPI (Table 1). Fasting C-peptide in 
Responders decreased from baseline (baseline 0.99±0.32 nmol/l, 5 months 0.59±0.23 
nmol/l, 12 months 0.59±0.21 nmol/l, 24 months 0.65±0.25 nmol/l; p<0.0001 for each vs. 
baseline). Following similar weight loss in the Non-Responder group reduction in C-peptide 
was also observed after weight loss (Table 1). 
 
Assessment of functional beta cell capacity  
The changes in plasma glucose for Responders vs. Non-Responders are shown in Figure 1 (A, 
B, C & D). The intended rapid increase of 2.8mmol/l was achieved in all groups for each of 
the 2 steps of the SISTA, followed in each case by stable hyperglycemia. The profile of insulin 
secretion rate at baseline, 5 months and 12 months is shown for Responders (Figure 1, 
panels E, F, G,&H) and Non-Responders (panels  I, J,K,&L).  
For Responders, maximal rates of insulin secretion in response to arginine bolus during 
hyperglycemia were 581 [480-811] pmol/min/m2 at baseline and 736 [542-998] 
pmol/min/m2 at 5 months. These two points were not significantly different (p=0.160), but 
an almost linear increase was observed across 12 months following weight loss such that 
rates increased to 942 [565-1240] pmol/min/m2 (p=0.028 compared with baseline). This 
improvement was maintained at 24 months (936 [635-1435] pmol/min/m2; p=0.023 vs. 
baseline) (Figure 2A). The maximal rate of insulin secretion for NDC was 1016 [857-1509] 
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pmol/min/m2, comparable to that for the Responders at 12 and 24 months (p=0.064 and 
p=0.244 respectively) (Figure 2A). Non-Responders showed no change in median maximal 
insulin responses (baseline 451 [296-691], 5 months 491 [388-629], 12 months 485 [387-
568], and 24 months 452 [347-616] pmol/min/m2). The difference between Responders and 
Non-Responders was significant by 5 months (p=0.002), and remained so at 12 months 
(p=0.001) and 24 months (p=0.002). The maximal insulin response in the diabetic Control 
group remained unchanged during 2 years follow up (546 [453-844], 567 [472-867], 559 
[429-835], and 488 [378-720] pmol/min/m2 respectively)(Figure 2A and Appendix Figure S3).  
Maximal insulin response to arginine in the Intervention group at 12 months correlated with 
first phase insulin response (r=0.6; p<0.0001), FPG and HbA1c (r=-0.4; p=0.003 for both). 
There was no correlation between maximal insulin response and total fasting TG at 12 
months. 
 
First phase insulin secretion 
First phase insulin secretion increased in Responders from 42 [4-67] pmol/min/m2 at 
baseline to 107 [59-163] pmol/min/m2 (p<0.0001) at 5 months, remaining constant at 12 
months (110 [59-201] pmol/min/m2; p<0.0001). At 24 month this was maintained in 
Responders (125 [65-166] pmol/min/m2; p<0.0001) (Figure 2B). The first phase response 
remained substantially lower than in the NDC (250 [226-429] pmol/min/m2; p<0.0001) 
compared with Responders at each time point after weight loss. There was no change in 
Non-Responders from baseline (23 [10-36] pmol/min/m2) either after weight loss at 5 
months (14 [7-33] pmol/min/m2; p=0.864), at 12 months (19 [-7-36] pmol/min/m2; p=0.746) 
(Figure 2B), or at 24 months (17 [6-33] pmol/min/m2; p=1.000).  The first phase insulin 
response of the diabetic Control group remained low and unchanged (25 [-5-61], 28 [3-43], 
29 [-11-60] and 35 [4-5] pmol/min/m2 respectively (Figure 2B and Appendix Figure S3).   
The median first phase insulin response was associated with ambient fasting plasma 
glucose, being 89 [59-188] pmol/min/m2 with FPG≤6.0mmol/l, 70 [45-81] with FPG 6.1-
6.9mmol/l, and 35 [-3-45] pmol/min/m2 with FPG≥7mmol/l. The relationship between first 
phase response and fasting plasma glucose is shown in Figure 3. First phase insulin response 
correlated significantly in Intervention group with FPG (r=-0.9; p<0.0001), HbA1c (r=-0.8; 
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p<0.0001), maximal insulin secretion (r=0.6; p<0.0001) and second step insulin response 
(r=0.4; p=0.022) at 12 month. There was no significant correlation with total fasting TG 
(r=0.3; p=0.098). In the diabetic Control group first phase insulin response did not change 
during the study (Figure S3). 
Second step insulin response  
There was a small but significant increase in median second step insulin response in 
Responders 3 [-9-29] pmol/min/m2 to 18 [8-34] pmol/min/m2 (p=0.011) at 5 months (Figure 
2C), remaining steady to 12 months (21 [1-39] pmol/min/m2 ; p=0.043), and with no 
significant change by 24 months (9 [-1-39] pmol/min/m2; p=0.256) vs. baseline. Median 
second step did not change significantly either in Non-Responders (baseline -6 [-14-8], 5 
months -2 [-8-6] , 12 months 1 [-1-7], 24 months -3 [-11-9] pmol/min/m2)  or in Controls (16 
[-2-33], 3 [-13-15], 8 [-7-50], and 17 [1-23] pmol/min/m2 respectively). There was a 
significant difference between second step in Responders and Non-Responders at 5 months 
(p<0.0001) and at 12 months (p=0.025) but not at 24 months (p=0.070).  
The median second step insulin response in NDC group was 68 [42-135] pmol/min/m2, 
greater than that of the Responders at every time point (p<0.0001).   
 
Discussion 
We report the gradual increase in assessed functional beta cell capacity over a 24 months 
period following weight loss-induced reversal of type 2 diabetes up to 6 years duration. The 
first phase insulin response followed a different time course, with those returning to non-
diabetic plasma glucose control exhibiting an early increase followed by stability from 5 to 
24 months. Unlike the assessed beta cell capacity, first phase insulin response improved 
significantly but remained around half of that of the non-diabetic controls. 
Studies of rodent beta cells in vitro suggest a relatively rapid resumption of insulin secretory 
function after removal of a metabolic stress (11). However, these studies typically involve 
cells from young animals and exposure to metabolic stress for a relatively short time. In 
human type 2 diabetes, exposure to excess lipid supply has been present for years or 
decades, affecting beta cells during middle age or more advanced years. This may account 
11 
 
for the prolonged phase of recovery here reported following weight loss and restoration of 
glucose control in type 2 diabetes. Given the recognised heterogeneity of beta cells (26), it is 
possible that some cells are at a more advanced stage of de-differentiation and the slow 
return to normal functional beta cell capacity reflects different rates of re-differentiation 
(27). It is of considerable interest that this process continues for at least 12 months after 
commencing negative calorie balance, in sharp contrast to the previously reported 
inevitable steady decline in beta cell number or function during maintained or increased 
body weight (1, 3, 4). No comparable observations have been made in previous studies, and 
the pathophysiologic mechanism underlying this requires investigation. GLP-1 
responsiveness was not examined in this study and dietary weight loss has previously been 
shown not to change this after return to non-diabetic glucose control (28, 29).  
The first phase insulin response did not completely normalise, although the degree of 
recovery was compatible with maintaining of non-diabetic blood glucose control. Not all 
beta cells are required to achieve a normal first phase insulin response, which can be 
achieved by rapid degranulation of some proportion of the whole. More detailed studies are 
required to determine the effect of an apparently adequate but sub-normal response during 
the post-prandial period. During 8 weeks of negative calorie balance in the Counterpoint 
study, we originally observed a gradually improving first phase insulin response over 8 
weeks in step with a gradually decreasing pancreas fat content (15). The extent of recovery 
appeared to be within the non-diabetic range but all the participants were in the first 4 
years after diagnosis, had previously been treated with diet or metformin only and were 
studied during continued low calorie diet which was more restricted (approximately 700 
kcal/day). The present data extend these findings, demonstrating that the recovery during 
the first few months is maximal in a group with duration of type 2 diabetes up to 6 years 
and previously treated with any number of anti-diabetes agents but not insulin (17). 
Subjects with pre-diabetes and first-degree relatives of people with type 2 diabetes have a 
subnormal first phase response sufficient to permit overall control of plasma glucose prior 
to onset of type 2 diabetes (30, 31) so it is possible that we may have observed return to the 
premorbid levels in those achieving remission.  
Metabolic stress on the beta cell can be produced by exposure to excess glucose or excess 
fat (11, 32, 33). In human type 2 diabetes it is almost certain that both contribute, although 
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initiation of the metabolic stress during normoglycemia likely to be via fat. Although the 
early sharp decrease in fasting plasma glucose levels will enhance the first phase response, 
this typically happens within hours with rapid recovery (34, 35). This was evident within 7 
days of commencing a very low calorie diet (15) although the subsequent return to near 
normal first phase insulin response to a glucose stimulus was observed to develop steadily 
over 8 weeks, in step with the gradual decrease to normal of the excess lipid exposure of 
the beta cells. In contrast, there was no change in muscle insulin sensitivity over 2 months 
following remission in Counterpoint (15). These observations were extended in the 
Counterbalance study which demonstrated continued normal hepatic insulin sensitivity but 
minor improvement only in muscle insulin sensitivity by 6 months following weight loss (16). 
The conditions of the insulin secretion test used permit assessment of beta cell function 
largely independent of tissue insulin sensitivity. As an indication of whole body insulin 
sensitivity, fasting plasma insulin, and hence its inverse, was not different between 
responders and non-responders at any time point (Table 1). 
The present studies were conducted on people with less than 6 years duration of diagnosed 
type 2 diabetes at the time of recruitment. The actual duration of diabetes will have been 
longer, and many participants reported delay in seeking medical advice after symptom 
onset. However, this will be common to all primary care populations with type 2 diabetes 
and time from diagnosis remains the practical yardstick. The protocol for DiRECT was 
informed by the Counterpoint study and the early results of the Counterbalance study which 
showed no return of first phase insulin secretion beyond 11 years of diagnosis (15, 16). Even 
within 6 years of diagnosis of type 2 diabetes, it is apparent that there are some individuals 
who are susceptible to a more rapid loss of beta cell function in response to the metabolic 
stress.  At 12 months, Responders had a significantly lower duration of diabetes than Non-
Responders (17). This durability over time to withstand the beta cell stress induced by the 
combination of high glucose and high fat exposure, suggests that exploration of the genetic 
basis of this beta cell behaviour is required. The majority of discovered genes associated 
with type 2 diabetes code for beta cell processes (36, 37) and this information on 
phenotypic heterogeneity between individuals offers a route to linking specific genes with 
durability under metabolic stress. An early indication of this phenomenon was provided by 
Unger’s demonstration of complete resistance to fat induced stress of islets isolated from 
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ZDF rats not predisposed to develop diabetes upon high fat feeding (38). It is possible that 
novel therapeutic targets may be identified to protect the beta cells of susceptible 
individuals, guided by genotyping.  
Attempts to study beta cell mass have evolved from post-mortem histological studies (3, 4, 
39), through techniques of fresh pancreas slice histology (40) and incubation, to imaging of 
beta cells in vivo (41). Although conceptually attractive, the latter lack precision and at 
present there is no practical method of quantifying in vivo. In contrast, the mass of beta 
cells which are functional can be assessed indirectly by metabolic tests (42, 43). An arginine 
bolus during hyperglycemia elicits a large spike in insulin secretion dependent upon 
functional beta cell mass. There is a tight correlation between the response seen at different 
levels of plasma glucose in type 2 diabetic and non-diabetic groups (44, 45). Although a true 
maximal response may be obtained at 25 mmol/l plasma glucose, the relative differences 
would be expected to remain. The SISTA test utilizes this defined response to permit an 
assessment of the functional beta cell capacity in vivo, and observation of the time course of 
recovery of function.  
 
In summary, the functional beta cell capacity as assessed in this study appeared to return to 
normal over 12 months in those who maintained weight loss-induced reversal of type 2 
diabetes. First phase insulin response improves more rapidly, but does not return to normal. 
Provided weight regain was minimised, both functional beta cell capacity and first phase 
insulin response remained stable at least up to 2 years with no evidence of any time-
dependent decrease in beta cell function.  
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 Baseline 5 months 12 months 24 months 
Resp=39 Resp=39 Resp=28 Resp=20 
Non-Resp=18 Non-Resp=18 Non-Resp=16 Non-Resp=12 
Control=26 Control=23 Control=20 Control=19 
- NDC=25 - - 
W
e
ig
h
t 
(k
g)
 
Resp 100.4±16.6 84.0±13.4 p<0.0001 85.5±16.2 p<0.0001 88.8±17.7 p=0.016 
Non-Resp 102.1±18.8 88.7±18.8 p=0.008 92.5±18.3 p=0.050 90.3±14.6 p=0.028 
Control 96.7±11.8 95.8±12.8 95.2±14.4 95.0±13.9 
NDC - 86.6±14.9 - - 
W
e
ig
h
t 
lo
ss
 (
%
) 
Resp - 16.0±6.1 p<0.0001 14.3±6.9 p<0.0001 10.5±6.1 p=0.016 
Non-Resp - 13.2±6.1 p=0.008 9.4±5.2 p=0.050 8.3±4.5 p=0.028 
Control - 1.1±3.1 0.8±4.4 1.7±5.5 
NDC - - - - 
H
b
A
1
c 
(%
) 
Resp 7.4±1.0  5.9±0.4 p<0.0001 5.8±0.3 p<0.0001 6.0±0.3 p<0.0001 
Non-Resp 7.9±0.8 *p=0.041 8.0±1.7 *p<0.0001 7.6±0.7 *p<0.0001 8.1±1.3 *p<0.0001 
Control 7.3±1.0 7.8±1.5 8.5±2.2 7.2±1.0 
NDC - 5.4±0.3 - - 
FP
G
 (
m
m
o
l/
l)
 
Resp 8.3±2.4 5.7±0.8 p<0.0001 5.6±0.6 p<0.0001 5.6±0.7 p<0.0001 
Non-Resp 9.3±2.8 8.8±2.6 *p<0.0001 8.5±1.8 *p<0.0001 9.3±4.0 *p<0.0001 
Control 8.3±2.0 8.4±2.3 8.5±2.2 8.0±2.0 
NDC - 5.1±0.4 - - 
FP
I (
p
m
o
l/
l)
 
Resp 86.4[55.5-145.5] 32.6[19.6-53.3] p<0.0001 28.9[17.6-65.7] p<0.0001 43.5[18.4- 61.6]p<0.0001 
Non-Resp 71.4[51.5-100.6] 33.8[20.7-43.3] p<0.0001 32.7[23.7-61.7] p=0.006 34.4[16.5-49.5]p=0.001 
Control 70.1[44.7-122.5] 58.4[36.2-83.0] 65.5[39.9-76.9] 44.7[31.3-64.5] p=0.050 
NDC - 16.4[10.0-37.2] - - 
Fa
st
in
g 
C
-p
e
p
ti
d
e
 
(n
m
o
l/
l)
 
Resp 0.99±0.32 0.59±0.23 p<0.0001 0.59±0.21 p<0.0001 0.65±0.25 p<0.0001 
Non-Resp 0.84±0.28 0.61±0.20 p=0.003 0.65±0.24 p=0.042 0.59±0.23 p=0.022 
Control 0.92±0.41 0.87±0.34 0.87±0.41 0.78±0.22 
NDC - 0.53±0.32 - - 
To
ta
l f
as
ti
n
g 
TG
 (
m
m
o
l/
l)
 Resp 1.71[1.15-2.29] 1.05[0.73-1.53] p<0.0001 1.09[0.75-1.62] p<0.0001 1.00[0.79-1.46] p<0.0001 
Non-Resp 1.57[1.25-1.99] 1.15[0.90-1.40] p=0.009 1.24[0.92-1.47] p=0.048 1.29[0.95-1.53] 
Control 1.06[0.81-1.58] 1.20[1.00-1.50] 1.21[1.00-1.91] 1.05[0.89-1.63] 
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NDC - 1.10[0.80-1.50] - - 
 
 
 
Table 1. Summary of weight change and fasting metabolic parameters for Responder, Non-
Responder, Diabetic Control and Non-Diabetic Control (NDC) groups at baseline, 5, 12, and 
24 months. Data for the NDC group are shown in the 5 month column as this group was recruited 
to have weight equivalent to the Intervention group after weight loss. Data shown as mean ± SD 
or median [IQ range].  Comparisons are shown for baseline to 5 months, baseline to 12 
months, and baseline to 24 months (p value) and for Responders vs. Non-Responders at 
each time point (*p value). N.B. The percentage of weight loss is shown for each group at 
that particular time point vs. the same number of participants at the baseline.  
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Legends to Figures 
Figure 1. Stepped insulin secretion test  
A, B, C, D: mean plasma glucose during SISTA in Responders       and Non-Responders 
 at baseline, 5 months, 12 months, and 24 months respectively. 
E, F, G, H: median insulin secretion rates (ISR) in Responders at baseline, 5 months, 12 
months, and 24 months respectively. 
I, J, K, L: median insulin secretion rates (ISR) in Non-Responders at baseline, 5 months,12 
months, and 24 months respectively. 
 
Figure 2.  Beta cell response during SISTA  
Comparison of the median maximal insulin response (A), median first phase insulin response 
(B), and median second step insulin secretion (C) in Responders, Non-Responders, Non-
Diabetic Controls (NDC) at baseline, 5 , 12 , and 24 months (p value in a box for Responders 
at each time point vs. baseline; p value without a box for Responders vs. Non-Responders at 
each time point).  
 
Figure 3. Relationship between fasting plasma insulin and first phase insulin secretion 
Fasting plasma glucose and first phase insulin secretion in the whole intervention group at 
12 months (n=48: Responders=28, Non-Responders=16, Relapsers=4) were plotted. The 
inset graph shows the log transformed data (7 individuals omitted due to negative 1st phase 
insulin secretion values unable to be logged). 
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